Abbott Laboratories (ABT) operating KPIs
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 28, 2026Score 14/3036% above fair value
$106.20+1.63 (+1.56%)
Close on Oct 30, 2026Market cap $183.77BP/E 34.1Yield 2.26%
Abbott Laboratories neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Worldwide Revenue ($M) ($M)
Form 8-K Quarterly Earnings Releases (Item 2.02 Revenue Tables) & Form 10-K/10-Q MD&A
Latest, FY2025
1,010
Period ended Dec 31, 2025
Change on a year earlier
+5.0%
962 in FY2024
History
10 years
Since FY2016
Sources
10
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Worldwide Revenue ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 1,010 | +5.0% | SEC Filing (0001628280-26-002982) ↗ |
| FY2024 | Dec 31, 2024 | 962 | +8.1% | SEC Filing (0001628280-25-002092) ↗ |
| FY2023 | Dec 31, 2023 | 890 | +15.6% | SEC Filing (0001628280-24-002009) ↗ |
| FY2022 | Dec 31, 2022 | 770 | -1.4% | SEC Filing (0001628280-23-001516) ↗ |
| FY2021 | Dec 31, 2021 | 781 | +11.3% | SEC Filing (0001104659-22-007648) ↗ |
| FY2020 | Dec 31, 2020 | 702 | -15.5% | SEC Filing (0001104659-21-007942) ↗ |
| FY2019 | Dec 31, 2019 | 831 | -3.8% | SEC Filing (0001104659-20-005717) ↗ |
| FY2018 | Dec 31, 2018 | 864 | +6.9% | SEC Filing (0001104659-19-002848) ↗ |
| FY2017 | Dec 31, 2017 | 808 | +43.3% | SEC Filing (0001104659-18-003691) ↗ |
| FY2016 | Dec 31, 2016 | 564 | – | SEC Filing (0001104659-17-023826) ↗ |
Breakdown
What makes up neuromodulation division (proclaim xr, eterna scs, liberta rc dbs) — worldwide revenue ($m)
- Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Organic / Comparable Sales Growth (%)4.8% · FY2025
- Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Reported Sales Growth (%)5.0% · FY2025
- Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Foreign Exchange Impact on Sales Growth (%)0.2% · FY2025
- Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — U.S. Revenue ($M)773 · FY2025
- Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — International Revenue ($M)237 · FY2025
Cite this data
StockData. (2026). Abbott Laboratories Neuromodulation Division (Proclaim XR, Eterna SCS, Liberta RC DBS) — Worldwide Revenue ($M) ($M), annual FY2016–FY2025 [Data set]. Compiled from Abbott Laboratories SEC filings and investor materials. https://stockdatahq.com/stocks/abt/kpis/md-nm-rev-ww
See every metric in the Abbott Laboratories KPI table. Data updated Oct 29, 2026.